JPS61194362A - Vacuum blood sampling tube - Google Patents

Abstract

PURPOSE:To separate serum and blood-clot by coagulating a whole blood specimen within a short time, by forming a tubular container from a polyethylene terephthalate or a copolymer thereof and allowing elaidic acid to be present on the inner wall surface of said container. CONSTITUTION:A cyclic org. compound represented by formula I (wherein A is a residue of a cyclic compound) and having two adjacent carbonyl groups present on the same plate substantially three-dimensionally is allowed to be present on the inner wall surface of a tubular container made of polyethylene terephthalate or a copolymer thereof. For example, a dispersion of elaidic acid and polycationic isopropyl alcohol represented by formula III is prepared and applied to the inner wall surface of a 10ml volume blood examination container made of a polyethylene terephthalate resin to be dried in air. When this container is used, a blood coagulation time is about half that of a glass container and serum separability is extremely well.

Description

DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to blood test containers, particularly vacuum blood collection tubes used to collect whole blood samples from subjects and separate serum by centrifugation. .

(Conventional technique tl#) In recent years, together with the remarkable progress of inspection technology, rhIW
#Blood tests such as biochemical tests, serum immunology tests, and hematology tests have become widely used and have greatly contributed to disease prevention and early diagnosis. Serum tests are the main body of blood tests, and the serum required for tests is usually obtained by coagulating blood collected in a blood test container and then centrifuging it to form blood clots (a gel mixture of fibrin and blood cells) with different specific gravities. Separated from the clumps).

As conventional vacuum blood collection tubes, those made of glass and those made of polymethyl methacrylate, which is a synthetic resin, are used, but these generally have the following X point.

After blood is collected, it takes a considerable amount of time for the blood to coagulate, making it impossible to carry out tests quickly, especially when it is necessary to carry out an emergency test. This has become a problem. Even with glass vacuum blood collection tubes, which are said to have a short blood coagulation time, it takes 40 to 60 minutes for blood to coagulate after it has been collected.
i.Resin vacuum blood collection tubes require being left for 4 hours or more before blood coagulates.

Another major feature of conventional vacuum blood collection tubes is that the entire coagulated tube is phase-separated from the serum and blood clots, which have different specific gravity, by means such as centrifugation. The separability of these materials is generally poor.

That is, gel-like fibrin or blood clots tend to adhere firmly to the tube wall, resulting in roughness that drastically reduces the amount of serum collected, and fibrin tends to remain in the serum. There were some defects that caused problems with biochemical tests. And IfnW! Even with glass vacuum blood collection tubes, which are said to have relatively good separation properties, the above-mentioned problems occur when used at low temperatures below 15° C., especially during winter.

On the other hand, inorganic fine particles such as glass are attached to the tube wall-C to shorten the blood coagulation time.

Additionally, a separation agent containing silicone oil, silicon compound powder, etc. is dispensed into the blood collection tube to improve the separation of serum. Such separating agents have thixotropic properties and [f111I! It is adjusted to have a specific gravity between that of blood clot and blood clot. Therefore, after the collected blood has coagulated, when the blood collection tube is placed in a centrifuge, the separating agent is absorbed into the blood.
It can move between the I layer and the blood clot layer and separate the serum layer. If it takes time to subject the thus separated serum to various tests, the blood collection tube is usually stored as is at a temperature of 4°C. However, the shelf life is relatively short, about 48 hours for glass blood collection tubes and 72 hours at most for polymethyl methacrylate vacuum blood collection tubes.

(Problems to be solved by the invention) This invention is intended to solve the above-mentioned conventional point X, and its purpose is to coagulate a collected whole blood sample in a short time and use a centrifugation operation. An object of the present invention is to provide a vacuum blood collection tube that can effectively separate serum and blood clots. Still another object of the present invention is to provide a vacuum blood collection tube that does not deteriorate the quality of serum even if it is stored as it is at low temperature for a long time after centrifugation, and is therefore effective as a serum storage container. There is a particular thing.

c) Means for Solving Problems) The gist of the present invention is to have a bottomed tubular container whose inside can be evacuated and a sealable stopper that maintains the reduced pressure state of the container, and the material of the tubular container is is polyethylene terephthalate or polyethylene terephthalate copolymer, and is represented by the general formula (I) on the inner wall surface of the container, and the two adjacent carbonyl groups are sterically located on substantially the same plane. A vacuum blood collection tube characterized by containing a cyclic organic compound, and having an internally evacuable fP, '& bottomed tubular container and a sealable stopper that maintains the reduced pressure state of the container, The material of the tubular container is polyethylene terephthalate or polyethylene terephthalate copolymer; a cyclic organic compound in the plane of
The above object is achieved by a vacuum blood collection tube characterized by the presence of an amine salt or an organic compound or organic polymer having quaternary nitrogen.

As the material for the bottomed tubular container constituting the vacuum blood collection tube of the present invention, polyethylene terephthalate having a repeating unit represented by the following structural formula is used.

Polyethylene terephthalate has high crystallinity, so in order to suppress this, a polyethylene terephthalate copolymer copolymerized with a crystallization inhibitor such as 1,4-cyclohequinane dimethanol in a proportion of 1 to 50% by weight is used. It's okay.

Polyethylene terephthalate has excellent gas barrier properties and can maintain a predetermined degree of reduced pressure.

In addition, it has excellent impact resistance compared to glass or polymethyl methacrylate, and there is no risk of breakage due to paper cutting or reduced pressure. Regarding disposal after use, incineration, which cannot be done with glass vacuum blood collection tubes, becomes possible.

As the sealable stopper for maintaining the reduced pressure state of the vacuum blood collection tube, it is preferable to use one obtained by molding gyl rubber or chlorinated butyl rubber using a conventional method.

In order to reduce the pressure inside the blood collection tube, the blood collection tube may be sealed with the rubber stopper in the reduced pressure container.

In the present invention, the cyclic organic compound represented by the above general formula that is present on the inner wall surface of the vacuum blood collection tube is used for the purpose of promoting blood coagulation, and the compound has two adjacent carbonyl groups and a residue. The homocyclic ring formed by the group A or F
'i may be any of the heterocyclic compounds, and such cyclic compounds may be monocyclic or polycyclic compounds, but in the present invention, at least two A cyclic compound in which the ring containing carbonyl carbon is a 6-membered ring or a 5-membered ring is preferably used.

The 6-membered cyclic compound preferably used in the present invention is represented by the following formula (Tel (however, RI'''R4 hydrogen, hydrocarbon group, polar substituent, or a residue in a polycyclic compound is shown). In the above formula, the hydrocarbon group is not particularly limited, but is preferably an alkyl group, and the above polar substituent is also not particularly limited. However, examples include a carboxyl group, a carboxylic acid ester group, a hydroxyl group, an amino group, a mercapto group, etc.Therefore, as preferred specific examples of compounds having an 0-quinone ring, for example, 0-quinone, the following general formula ( However, gallic acid alkyl ester oxides represented by RsFi alkyl group), elladic acid partial oxides and complete oxides represented by the following formulas, and 1,4-di Examples include (3,4-dihydroxyphenyl)2,3-dimethylbutane partial oxide and complete oxide.

Further, a preferred specific example of a homocyclic compound in which the ring containing two carbonyl carbon atoms is a 5-membered ring includes 1,2,3-triketohydroindene represented by the following formula.

Document ζ, a list of heterocyclic compounds that can be preferably used in the present invention, the following general size ■0 (However, R6#-1t indicates hydrogen, a hydrocarbon group, or a residue in a polycyclic compound, and R7 and R8 represents hydrogen, a hydrocarbon group, a polar substituent, or a residue in a polycyclic compound.

), where the above hydrocarbon group and polar substituent are the same as above.

A preferred specific example of such a compound is isatin represented by the following formula.

All of these compounds in this group have two carbonyl groups that are sterically identical or approximately the same on the same plane, and the detailed mechanism of action is unknown. , exhibits specific effects on blood coagulation factors. On the other hand, an example of a compound that has adjacent carbonyl groups in the molecule but is not suitable for the purpose of the present invention because they are not on the same plane is, for example, 1,2-diketocyclohexane represented by the following formula. .

In this case, the alicyclic linkage that connects two adjacent carbonyl groups has a considerable 7-lexiperity, and therefore, these carbonyl groups are in gauche positions with respect to each other due to steric repulsion, and are not on the same plane. This compound does not exhibit any specific effect on blood coagulation factors. It is speculated that these things* are probably due to the fact that the two adjacent carbonyl groups in special steric positions have a special relationship with a specific site of the blood coagulation factor, which is a protein. .

In the present invention, in addition to the bicyclic compound, an amine salt or an organic compound or organic polymer containing quaternary nitrogen may be present on the tube wall surface.

As the amine salt, any of the inorganic acid salts of #IJ primary, secondary, and tertiary amines can be used, and specific examples include hydrohaginic acid such as hydrochloric acid, sulfuric acid, sulfurous acid, etc. Salts of inorganic acids and salts of organic acids such as formic acid and acetic acid can be mentioned.

The organic residue of the amine salt is usually an alkyl group, but this alkyl group may also be an alkyl group containing a different element such as an imino group or an ether group, and the amine salt shall include an inner salt. .

Therefore, specific examples of preferable amine salts include hexadecyldimethylamine salts and salts represented by the following formula %, and tetotsudasildi(aminoethyl)glycine represented by the following formula % ([). can.

Further, the organic monomer having a quaternary nitrogen is preferably a tetraalkylammonicum, but it may partially have an aryl group, and as mentioned above, the alkyl group is an imino group. or an alkyl group containing a different element such as an ether group. For example, a preferred specific example is dodacyltrimethylammonicum chloride represented by the following formula %.

Organic polymers having quaternary nitrogen preferably have the following general formula (%) (where R9-R12 are hydrogen or anolecyl group, (indicates h-) It is a polycation having a repeating unit represented by:

In particular, a polycation having a repeating unit represented by the following formula is preferably used.

In the present invention, in order to make the above-mentioned cyclic organic compound, amine salt, or monomer or polymer containing quaternary nitrogen present on the inner wall of the container, each component must be dissolved in a suitable binder or solvent. Alternatively, it may be applied in a dispersed state by spraying or dipping.

The use of the above-mentioned cyclic organic compounds and amine salts or compounds containing quaternary nitrogen is related to the amount of blood that is later injected into the blood collection tube, and the amount of blood that is applied to the inner wall of the blood collection tube is In both cases, II is at least 1X10 l per 1 g of blood, and when it is less than this, the effect of promoting blood coagulation is poor. However, if too large a quantity is present, it may cause various problems in blood tests, so it is preferable that the amount is less than 1 g of IXlG.

According to the method of the present invention, the amine salt or the quaternary nitrogen-containing monomer or polymer described above adsorbs and neutralizes heparin when it comes into contact with blood containing octophosphorus,
It precipitates together with this and quickly eliminates the action of heparin, thereby restoring normal blood coagulation function, and the above-mentioned cyclic compounds have specific effects on blood coagulation factors. Second, the blood in the blood test container is coagulated within a short period of time, so that serum can be obtained with good separation by centrifugation.

To explain this point in more detail, in normal blood, #JEx! is immediately coagulated due to contact between the blood and the inner wall surface of the blood container. The activation of the factor progresses, and this becomes the starting point for blood coagulation to progress in a chain reaction. Ultimately, thrombin generated by activation of prothrombin acts on fibrinodan, forming an insoluble fibrin network. Complete coagulation.

On the other hand, it is said that normally 1 to 10 units of heparin exist per 10 ee in the blood of patients receiving heparin administration, and in this way, in the case of blood containing heparin, heparin acts cooperatively with antithrombin present in the blood, significantly inhibiting the action of thrombin. In this way, heparin is said to not only inhibit the action of thrombin, but also inhibit the action of other coagulation factors. However, according to the method of the present invention, as mentioned above, the conversion of fibrinodan to fibrin does not occur, and as a result, blood does not coagulate, making it impossible to separate serum. Since thrombin and other blood coagulation factors are adsorbed to amine salts or quaternary nitrogen-containing monomers or polymers and removed from the blood, the normal blood coagulation effect is restored, and the above-mentioned Blood coagulation may be significantly promoted by the specific action of cyclic organic compounds.

As IJ is removed from the blood, blood coagulation factors are rapidly activated, and the time required for coagulation after blood is collected into a container is reduced. In addition, the separation of serum and blood clots becomes extremely easy, and the problem of [f[Ll# components being mixed in the separated and collected serum is also solved.Furthermore, according to the method of the present invention, For example, as a result of sufficient contraction of blood clot components, serum collection is also significantly increased.

However, in many biochemical tests, only serum is used, and the serum is drawn out with a pipette after centrifugation using a blood test container, but the preparative separation operation is time-consuming. It is not suitable for transportation as is.

For this purpose, a barrier-forming agent is present in the container. Separation!
Type 12 Kajiyaku has thixotropic properties and is a composition that forms a partition between serum and blood clot by centrifugation, and forms a partition so that serum can be separated by decantation. It is a substance that forms

This partition forming agent consists of a thixotropic agent and a viscous liquid.

Thixotropic agents include silica, alumina,
glass, talc, kaolin, bentonite, titania,
Inorganic powders such as zirconitum, asbestos, and carbon black, and organic powders such as styrene resins, acrylic resins, and vinyl chloride X resins are preferably used.

Among these thixotropic agents, fine silica powder shows the best results. Fine silica powder is a fine powder containing silicic anhydride as a main component, which has been subjected to hydrophobization treatment by Dalato reaction or coupling reaction as necessary, and the natural state of the raw material is powder. It doesn't matter whether it is lumpy or lumpy.

However, the average particle size of these thixotropic agents is 1
It is preferable that mp -100μ.

If it is smaller than 1 mμ, it is difficult to handle, and when mixed with the viscous liquid described later, it tends to aggregate and form secondary particles, making uniform dispersion difficult. This is because the dispersion stability is poor and the partition wall modifier as a whole lacks uniform fluidity.

Furthermore, when the specific surface area is 10 to 5 Q Orrl/p, excellent thixotropy can be obtained.

However, when the ground surface area becomes smaller than 1 ord/f, the inorganic fine powder becomes difficult to mix with the viscous liquid material, which is a component of the separation composition, and prevents sedimentation. Anything larger than y tends to aggregate, making uniform dispersion in a viscous liquid difficult.

The viscous liquid may have a strong interaction with the thixotropic agent, or may not have a strong interaction with the thixotropic agent, or may have good compatibility. Both may be used in combination.

It has a strong interaction with the thixotropic agent,
Even if a certain thixotropic agent is mixed with a certain viscous liquid and uniformly dispersed, and then centrifuged for 30 minutes at a rotation speed of 4000 r/p/m in a centrifugal separator with an arm length of 1 OclL, the components of the mixture will not be removed. This refers to a case where no bias is observed in the distribution state.

The cause of this interaction is not yet clear, but between materials with hydrophilic groups it is mainly due to hydrogen bonding, and between materials without hydrophilic groups it is due to the cohesive force caused by the molecular structure. It is assumed that this is the cause.

Thixotropic viscous liquids that have a strong interaction with the agent include acid-modified liquid polymer substances such as acrylic resin oligomers, polyester oligomers, liquid polyisoprene, liquid polybutene, and liquid polygetadiene, especially maleic acid-modified substances; Examples include animal and vegetable oils such as soybean oil, linseed oil, safflower oil, and fish oil, acid-modified products of the animal and vegetable oils, liquid polymer substances such as liquid polybutene and liquid polygetadiene, and epoxy-modified products of the above-mentioned animal and vegetable oils. When the imparting agent is an organic powder, examples thereof include oligomers of the same type as the thixotropy imparting agent, such as styrene oligomers for polystyrene, and it is preferable that all of them have a viscosity of 200 cps or more.

When such a viscous liquid is used, the thixotropic agent and the viscous liquid will not separate and will not be stored at °C.

Viscous liquids that do not have strong interactions with thixotropic agents can also be used in the presence of water-insoluble amine compounds in the present invention. Examples of such viscous liquids include liquid polymer substances such as liquid rough-in, liquid polyisoprene, liquid polybutene, and liquid polybutadiene, styrene oligomers, and chlorinated products thereof. In the case of liquid paratwin and its chlorinated products, the viscosity of both is l 000 (p
It is preferable that it is s or more.

Furthermore, it is also possible to use a mixture of a viscous liquid that has a strong interaction with the thixotropic agent and a viscous liquid that has good compatibility therewith and does not have a strong interaction with the thixotropic agent. In this case, good compatibility is defined as the case where no phase separation occurs even if the two viscous liquids are mixed and dispersed uniformly and then left at room temperature for a week. When using a mixture of a viscous liquid that has a strong interaction with the drug and a viscous liquid that has good compatibility with the drug and does not have thixotropic properties, the viscosity over time The stability of the vines is excellent. In this case, the mixing ratio of both viscous liquids is set within a suitable range taking into account the strength of interaction with each thixotropic agent, but in general, the thixotropic agent 6 has a strong interaction. viscous liquid substance i
10 to 600 parts by weight of a viscous liquid that does not have a strong interaction with the thixotropic agent is used per oo parts by weight.

By the way, the stability of the viscosity over time is further improved by using a water-insoluble amine compound.

Preferred water-insoluble amine compounds include those having one or more alkyl groups of carbon and 8 or more in the molecule, such as dodecylamine, tetradecylamine, hexadecylamine, octadecylamine, dodecyldimethylamine,
Examples include tetradecyldimethylamine, octadecyldimethylamine, polyoxyethylene octadecylamine, and trioctylamine.

Although the above-mentioned amine compound is used, it has the property of being easily adsorbed on the surface of the thixotropic thickening agent, and has an interaction with both the thixotropic thickening agent and the viscous liquid, making it difficult to stick. By acting on the stability of viscosity over time.

In particular, amines with an alkyl group having 8 or more carbon atoms are suitable because they are highly water-insoluble and do not dissolve in separated serum or plasma. It is inferred that the long chain alkyl group of the amine compound adsorbed on the surface of the thorns has the function of stabilizing the interaction between the thixotropic agents.

By using the above-mentioned amine compound, the viscosity stability of the barrier U forming agent over time is significantly improved, and as a result, centrifugal separability and barrier wall stability are improved.

The ratio of the thixotropic agent to the viscous liquid is 2 parts by weight of the thixotropic agent per 100 parts by weight of the viscous liquid.
~15 parts by weight, and when a water-insoluble amine compound is used in summer, it is preferably α02 to 5 parts by weight.

Also, interval Ij! The specific gravity of forming cutting is generally LO at room temperature.
3 to LO8, which is required to form a partition wall [f[
l? This is due to the need for a specific gravity intermediate between II and blood clot.

When such a septum-forming agent is used, serum and blood clots are separated by centrifugation, and a septum is formed at the interface between serum and blood clots. Since it does not collapse even when tilted, serum can be easily separated by decantation, etc.

To obtain the vacuum blood collection tube of the present invention, first, polyethylene terephthalate or polyethylene terephthalate copolymer is molded with a bottom by an appropriate molding method such as injection molding, blow molding, two-compression molding, transfer molding, vacuum molding, or casting molding. A tubular container is formed into a rose-shaped container, and a blood coagulation promoter such as a cyclic organic compound is present on the inner wall surface of the molded container by the method described above. Just apply.

In addition, even if the partition forming agent is dispensed into the container from the beginning,
It may be added when performing a centrifugation operation after the collected blood is coagulated.

(Effect) When blood is collected from the subject into the thus obtained vacuum blood collection tube whose interior is in a reduced pressure state and left at room temperature, approximately 2
Blood clots in 0-30 minutes. When this is centrifuged, it is separated into serum and blood clot.

The material of the container for the vacuum blood collection tube of the present invention is polyethylene terephthalate resin, which has low hydrophilicity. No molecular adsorption layer is formed. Therefore, the septum-forming agent and the inner wall of the blood collection tube form a strong (ζ) close contact, completely separating serum and blood clot. Therefore, inorganic ions from the blood clot enter the serum layer through the water molecule adsorption layer on the inner wall. Therefore, it is possible to store serum separated by centrifugation at low temperature for a long time.Using the vacuum blood collection tube of the present invention, it is possible to store serum at 4°C for more than 340 hours. It is possible.

This corresponds to about 7 times as much as when using a glass blood collection tube. On the other hand, interval 11! When using a conventional vacuum blood collection tube into which a diaphragm is dispensed, the adsorption layer of water molecules is covered with cedar bark, so the septum-forming agent does not adhere firmly to the inner wall of the blood collection tube, and as a result, the line breaking effect is not sufficient. Inorganic ions from blood clots are not obtained from blood WII! It is thought that it diffuses to I. As a result, separated serum cannot be stored for a long time.

In this way, by using the vacuum blood collection tube made of the specific material of the present invention, it is possible to coagulate the entire collected sample in a short time and to effectively separate serum and blood clots by centrifugation. After separation, the blood collection tube can be used as a storage container for serum.

(Example) The invention will be explained below with reference to examples.

Example 1 Elazic acid oxide represented by the above formula (■) and the above formula (X
An isopropyl alcohol dispersion of a polycation represented by VI[) was prepared, and this was coated on the inner wall surface of a blood test container made of polyethylene terephthalate resin having a volume of 10d and air-dried.

The amount of the above compound attached to the inner wall surface was 5×1.
Then, the vacuum blood collection tube was adjusted by evacuating the inside and sealing it with a butyl rubber tube.The degree of vacuum inside the tube was set so that the amount of blood to be collected was 6d. After collecting fresh human blood, it was left at 20°C, and the time required for the whole blood to stop flowing completely was measured as the blood retention time to evaluate blood coagulation. Immediately after blood coagulation, blood coagulation was evaluated. Centrifugation was performed for 5 minutes at a rotation speed of 3000 revolutions/rotation, and the state of lf[L pre-separation was observed.

As is clear from the results in the Example 1 column of Table 1, blood coagulation was extremely rapid in the obtained vacuum blood collection tube, and the serum separation state was also good.

Example 2 Specific gravity at 20°C is LO2 and viscosity is 10000 cps
Epoxidized soybean I containing 70 parts by weight of chlorinated polyligten with a specific gravity of LO and a viscosity of 17 Q Ocps at 20°C.
121 parts by weight of It, 9 parts by weight of hydrophobized finely powdered silica, and 2 parts by weight of trioctylamine α were kneaded in a Miki roll mixer to obtain a partition forming agent having a specific gravity of LO6 at 20°C.

Ta.

This partition-forming agent was injected into a container obtained in the same manner as in Example 1, and the internal vacuum was set so that the amount of blood collected was 6 d, and the container was sealed with a butyl rubber stopper.

Using the thus obtained vacuum blood collection tube, Example 1
Blood coagulation and serum separation status were observed in the same manner as above. Next, in order to observe the performance as a [f[1lfl] storage container, after serum separation, it was stored under refrigeration at 4°C, and the IfrL supernatant was fractionated immediately after the start of storage, and on the 3rd, 7th, and 144th day of storage. Then, LDH%K, which is listed as a biochemical test item, was measured.

As is clear from the results in the column of Example 2 in Table 1, the obtained vacuum blood collection blood liI solidified quickly and the serum separation state was also good. Moreover, as is clear from the results of the shelf of Example 2 in Table 2, LDH.

It showed a stable K value and was good as a serum storage container.

Comparative Example 1 Using a commercially available 6d4$ blood glass vacuum blood sampling tube, blood R homogeneity and If[Lw# isolated lesions were observed in the same manner as in Example 1. Next, in the same manner as in Example 2, lf[1
The performance as a storage container was observed.

The results are listed in the Comparative Example 1 column of Tables 1 and 2.

Table 1 Table 2 (Effects of the Invention) According to the present invention, all collected samples can be coagulated in a short period of time, and serum and blood clots can be effectively separated by centrifugation. A vacuum blood collection tube is obtained.

Furthermore, the vacuum blood collection tube of the present invention is also effective as a storage container for serum after centrifugation, and the obtained serum can be stored at low temperatures for a long period of time.

that's all

Claims (1)

[Claims] 1. The tubular container has a bottomed tubular container whose inside can be evacuated and a stopper that can be tightly closed to maintain the reduced pressure state of the container, and the material of the tubular container is polyethylene terephthalate or polyethylene terephthalate copolymer. The inner wall of the container is represented by the general formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (However, A represents the residue of a cyclic compound.) 1. A vacuum blood collection tube comprising a cyclic organic compound in which adjacent carbonyl groups are sterically located on substantially the same plane. 2. The vacuum blood collection tube according to claim 1, wherein the stopper is made of butyl rubber or chlorinated butyl rubber. 3. The vacuum blood collection tube according to claim 1, wherein a septum-forming agent is provided in the container. 4. The vacuum blood collection tube according to claim 3, wherein the septum-forming agent contains a thixotropic agent and a viscous liquid. 5. The vacuum blood collection tube according to claim 3, wherein the septum-forming agent contains a thixotropic agent, a viscous liquid, and a water-insoluble amine. 6. It has a bottomed tubular container whose inside can be evacuated and a sealable stopper that maintains the reduced pressure state of the container, and the material of the tubular container is polyethylene terephthalate or polyethylene terephthalate copolymer, and the inside of the container is On the wall, there are general formulas (I) ▲mathematical formulas, chemical formulas, tables, etc.▼ (where A indicates the residue of a cyclic compound), and the above two adjacent carbonyl groups are sterically a cyclic organic compound that is substantially on the same plane;
1. A vacuum blood collection tube comprising an amine salt or an organic compound or organic polymer having quaternary nitrogen. 7. The vacuum blood collection tube according to claim 6, wherein the stopper is made of butyl rubber or chlorinated butyl rubber. 8. The vacuum blood collection tube according to claim 6, wherein a septum-forming agent is provided in the container. 9. The vacuum blood collection tube according to claim 8, wherein the septum-forming agent contains a thixotropic agent and a viscous liquid. 10. The vacuum blood collection tube according to claim 8, wherein the septum-forming agent contains a thixotropic agent, a viscous liquid, and a water-insoluble amine.